Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ROCHE-CE-amrk-ApoE4

More Like This

PR Newswire associated0

Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

Business Wire logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Business Wire logo

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

AliveDx Receives IVDR-CE Mark for Multiplexed Assay to Accurately Detect Celiac Disease (CD) on the MosaiQ® System

PR Newswire associated0

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

PR Newswire associated0

MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European Union and other CE mark accepting countries

LifeArc and Global Alzheimer's Platform Foundation - Scientists test whether a finger prick blood test could be used to help diagnose Alzheimer's disease before symptoms begin

PR Newswire associated0

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research